Episode Details

Back to Episodes
Episode 86 - David de Vries - Tr1X

Episode 86 - David de Vries - Tr1X

Published 11 months, 2 weeks ago
Description

On this episode we're joined by the Co-Founder & CEO of Tr1X, David de Vries.


David and the team are building on the Nobel Prize winning research into T-reg cells of Fred Ramsdell, Shimon Sakaguchi, and Mary Brunkow, pushing that science forward by translating a Type-1 regulatory T cell program into the clinic with one goal - lasting immune balance for patients.


Their lead program TRX103 is in ph1/2 trials for GvHD and Refractory Crohn's, whilst they just received another IND clearance for TRX319, an allogeneic CD19 CAR-Tr1 therapy, to tackle Progressive MS. Tr1X pick hard problems on purpose & these indications demonstrate that.


David is an impressive leader, having co-founded Arine, and was nominated recently in BioSpace's 40 under 40 list. Tr1X are one to watch, we hope you'll enjoy the episode!

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us